Treatment of asthma in childhood  by Edwards, A.M. & Filcek, S.A.L.
Respiratory Medicine (1995) 89, 153-l 55 
Letters to the Editor 
Dear Editor 
Tuberculous empyema presenting after oleothorax 
Forouhi and colleagues (1) describes a 78-year-old 
man who presented in 1989 with a discharging chest 
wall sinus and an associated pleural effusion. He had 
originally been treated in 1927 with an oleothorax 
after failure of pneumothorax therapy for pulmonary 
tuberculosis. They aspirated his pleural fluid, which 
was mineral oil; on culture it yielded Mycobacterium 
tuberculosis, sensitive to the usual chemotherapeutic 
agents. Despite treatment, he died. 
The authors attribute his death to recognized com- 
plications of oleothorax therapy, but might not the 
entire illness have been avoided by a year of prophy- 
lactic isoniazid or other suitable chemotherapy, 
administered sometime in the intervening decades? 
Isn’t the real cause of death a failure of public health 
practice? 
Are there other untreated ‘old tuberculars’, 
similarly at risk? 
R. CARLEN 
17 Main Street 
Sayville 
New York 11782-2501, U.S. A. 
10 June 1994 
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Dear Editor 
Analgesia and sedation in fibre optic bronchoscopy 
We read with interest the recent short report by 
Williams et al. on the acceptability of intravenous 
midazolam for fibre optic bronchoscopy (1). How- 
ever we are somewhat surprised by the method in 
which they undertake the procedure. It is well recog- 
nized that the topical nasal anaesthesia is perceived 
as the most unpleasant part of the procedure (2), 
although this may be improved by using lignocaine 
gel (3-5). 
An alternative approach which we routinely follow 
is to give the intravenous sedation prior to applica- 
tion of 4% lignocaine solution via a Mackintosh 
atomizer. The nares are sprayed and after a few 
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minutes to allow for anaesthesia, the atomizer is 
placed in the nostrils and the patient is encouraged to 
sniff during spraying, this is usually followed by a 
small cough. Good nasal anaesthesia is achieved and 
patients appear to cough less when the cords are 
formally sprayed via the bronchoscope, probably as 
the nasal lignocaine aerosol has already partially 
anaesthetized the larynx. Moreover as the patient 
is already sedated they have no recollection of 
either the spraying of the nose or passage of the 
bronchoscope. 
The technique we describe is clean and simple to 
follow, allows a clear view, produces effective anaes- 
thesia and is exceptionally well tolerated. We would 
recommend this technique of upper airway anaesthe- 
sia and suggest that it is logical to use sedation prior 
to the most unpleasant part of the procedure. 
J. DIHENKER AND M. B. ALLEN 
St. Luke’s Hospital 
Little Horton Lane 
Bradford BD5 ONA, U.K. 
28 July 1994 
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Dear Editor 
Treatment of asthma in childhood 
In their recent paper (1) Agertoft and Pedersen 
describe 216 children with mild and moderate asthma 
who were followed for l-2 yr (run-in) before being 
given budesonide (BUD) for 3-6 yr. The dose of 
BUD started at 800 fig day ’ and was titrated up or 
down according to the degree of asthma control. The 
children receiving BUD were improved compared 
both with run-in and with a group of ‘control’ 
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children who were selected on the basis of choice of 
treatment, their parents not wanting their child to 
receive inhaled corticosteroid ‘because they were 
afraid of side effects.’ Since this was not a random- 
ized study, the comparison with the ‘control’ group 
could be biased in either direction. 
On the basis of results in the run-in and ‘control’ 
groups, the authors suggest that ‘suboptimally 
treated asthma may result in irreversible airway 
obstruction’ (though no attempt was made to assess 
reversibility). Their treatment consisted of theophyl- 
line (56 and 64% during run-in and ‘control’, respec- 
tively), sodium cromoglycate (40%, 58%) and oral 
&agonist (46%, 42%); it is not clear whether these 
children had access to inhaled &agonist. These 
treatments were given throughout the study ‘accord- 
ing to the normally recommended guidelines’ as they 
existed in 1989 (2) although these have since been 
superseded by more recent recommendations (3-5). 
We agree that the treatment in these groups is, by 
present standards, suboptimal. It would, however, be 
incorrect to imply from these results that treatment 
with sodium cromoglycate could lead to an 
‘irreversible’ loss in lung function. Konig (6) recently 
described a favourable long term outcome after 
treating children optimally for 3-14 yr with sodium 
cromoglycate. Konig, who did measure reversibility, 
showed improved or normal pulmonary function and 
‘no evidence of irreversible obstruction after up to 
14 yr of follow-up.’ These results support earlier 
findings (7). 
Agertoft and Pedersen’s study cannot be regarded 
as a direct comparison of BUD and sodium cromo- 
glycate, nor does it show that lung function, or any 
other aspect of asthma, deteriorates with sodium 
cromoglycate. Further, it does not assess the effec- 
tiveness of current treatment recommendations for 
children with asthma. All Agertoft and Pedersen 
did show were the benefits of treating poorly con- 
trolled asthma with intensive anti-inflammatory 
therapy. 
The authors state that, after starting on BUD, no 
children required sodium cromoglycate and the use 
of theophylline and oral &agonists was significantly 
reduced. This is not surprising since, according to the 
study design, treatment with sodium cromoglycate 
was always stopped when BUD was started. Theo- 
phylline and/or oral &agonists were only added if 
high-dose BUD did not result in good control of 
asthma, and in such children the BUD dose could be 
increased. The number of children requiring an 
increase in dose is not stated although a high-dose 
(>8OOpg; mean 1025 pug day ~ ‘) group was analysed 
for the effect of BUD on growth. 
On growth, analysis of the annual change in height 
standard deviation scores (SDS) showed that, com- 
pared with run-in and low doses (<4OO,ug day - ‘), 
‘high’ doses of BUD (>4OOpg day ‘) were associ- 
ated with a significant reduction in the change in 
height SDS. As with symptoms and lung function, 
the comparison of effects on growth is not between 
BUD and sodium cromoglycate treatment but 
between well and poorly controlled (undertreated) 
asthma. It is well known that asthma, if not well 
controlled, will itself stunt growth. The SDS analysis 
does not include data from normal children, although 
a separate group of normal children was analysed for 
other growth variables. The final, 4-yr mean daily 
doses were 447 pg from Turbuhaler and 612 lug from 
Nebuhaler; thus, both devices are delivering doses 
above the safe cut-off point, as defined in the paper, 
of ‘up to 400 ,ug day I’. 
Finally, the authors wonder whether BUD will 
help the children to grow out of their asthma. The 
clinical benefits described in these children probably 
depend upon continued intake of inhaled steroid. A 
recent study (8,9) showed that although 60% of 
children had a remission of symptoms during up to 
3 yr of treatment with BUD 600 pg day - ‘, two- 
thirds later relapsed and at the end of follow-up only 
about half of these had normal lung function, while 
airway hyperresponsiveness remained abnormal in 
the majority of patients. When BUD was tapered off 
over 2 months and discontinued in some children, 
their asthma deteriorated rapidly. At the end of 6 
months, airway calibre and responsiveness had fallen 
to the same levels as before the 3 yr of BUD treat- 
ment; children who were in a complete remission 
appeared to decline as rapidly as those who had not 
normalized on inhaled steroid. 
Asthma is probably a lifelong problem and the 
risks of long-term treatments must be weighed 
against their benefits. In this context Agertoft and 
Pedersen’s study can only be regarded as short term 
and highlights the need for well controlled, long term 
studies of intervention in childhood asthma (10). 
A. M. EDWARDS AND S. A. L. FILCEK 
Fisons plc Pharmaceutical Division 
12 Derby Road 
Loughborough LEII OBB, U.K. 
2 August 1994 
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The genus Chlamydiaceae consists of three species, 
all of which may cause disease in humans; Chlumydiu 
pneumonia, C. psittaci and C. trachomata. C. pneumo- 
nia, first isolated in the 1960s described as the 
TWAR agent in 1986 and considered a strain of 
C. psittaci at that time, has since been recognized as a 
separate species, and therefore may account for a 
significant proportion of previously-diagnosed cases 
of C. psittaci infection (1). 
We wonder whether the recent case report of acute 
renal failure due to C. psittaci (2) was in fact due to 
C pneumonia. We had experience of a similar case of 
a 61-year-old man who had been exposed to cages 
containing bird excrement and plumage, while repair- 
ing pipes in a pet shop. Our patient developed acute 
renal failure associated with a respiratory infection. 
After a period of assisted ventilation, renal replace- 
ment with dialysis and antibiotic therapy, he made a 
complete recovery with normalization of his renal 
function. Antibody titres, using complement fixation, 
to Chlamydia group antigen confirmed a significant 
rise from l/10 to l/80, but species-specific serology of 
the sample indicated C. pneumonia with a titre of 
l/10280 and a titre of 11280 for C. psittaci, due to 
cross reactivity with common antigen. Therefore, 
despite the strong epidemiological history, a 
diagnosis of psittacosis was excluded. 
It is clear that the diagnosis in this case, and hence 
the reason for reporting the case, hangs on the 
confirmation of psittacosis. The authors give no titres 
regarding species-specific serology of Chlamydia 
group antigen, and we wonder whether it would be 
helpful to ascertain the exact cause of the initial 
infection using species-specific serology, recognizing 
its limited availability at present. 
S. BHANDARI 
Leeds General Injirmary 
Leeds, UK. 
13 September 1994 
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